<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557618</url>
  </required_header>
  <id_info>
    <org_study_id>202007034</org_study_id>
    <nct_id>NCT04557618</nct_id>
  </id_info>
  <brief_title>Auricular VNS Following Subarachnoid Hemorrhage</brief_title>
  <official_title>Transcutaneous Auricular Vagus Nerve Stimulation Following Spontaneous Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Huguenard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether non-invasive auricular vagal nerve stimulation lowers&#xD;
      inflammatory markers, and improves outcomes following spontaneous subarachnoid hemorrhage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vagal nerve stimulation (VNS) has been studied in several inflammatory conditions, and has&#xD;
      been implemented in animal models of subarachnoid hemorrhage (SAH) with promising results.&#xD;
      The purpose of the proposed study is to determine how applying auricular VNS in patients&#xD;
      presenting with spontaneous SAH impacts their expression of inflammatory markers in their&#xD;
      blood and cerebrospinal fluid (CSF), and how it impacts their clinical course and outcomes.&#xD;
&#xD;
      This study will involve randomizing patients to stimulation with VNS, or sham stimulation.&#xD;
      Blood and CSF will be collected on admission, and serially throughout the patient's&#xD;
      admission. Clinical events tracked during the hospital stay include development of cerebral&#xD;
      vasospasm, need for CSF diversion via a shunt, stress-induced cardiomyopathy, and development&#xD;
      of stroke or global cerebral ischemia. Outcomes following admission will include functional&#xD;
      scores at discharge, and at follow-up visits for up to 2 years after discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to either stimulation or sham stimulation arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>All participants will be fitted with an auricular stimulator, but blinded to whether they are receiving stimulation or not. Outcome scores will be assessed and recorded by clinicians blinded to treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory markers in the serum on admission</measure>
    <time_frame>On hospital day 1</time_frame>
    <description>IL-12, GM-CSF, IFN gamma, IL-1b, IL-10, IL-13, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-8, TNF alpha from blood draws</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in inflammatory markers in the serum</measure>
    <time_frame>Through hospital admission, average of 4 weeks</time_frame>
    <description>IL-12, GM-CSF, IFN gamma, IL-1b, IL-10, IL-13, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-8, TNF alpha from blood draws</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in the CSF on admission</measure>
    <time_frame>On hospital day 1</time_frame>
    <description>IL-12, GM-CSF, IFN gamma, IL-1b, IL-10, IL-13, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-8, TNF alpha from cerebrospinal fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in inflammatory markers in the CSF on admission</measure>
    <time_frame>Through hospital admission, average of 4 weeks</time_frame>
    <description>IL-12, GM-CSF, IFN gamma, IL-1b, IL-10, IL-13, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-8, TNF alpha from cerebrospinal fluid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral vasospasm</measure>
    <time_frame>Through hospital admission, average of 4 weeks</time_frame>
    <description>Presence of vasospasm based on any of the following criteria: 1) Radiographic evidence of vasospasm on CT angiogram or catheter angiogram, 2) Need for blood pressure augmentation or hypervolemia, 3) Need for intraarterial or intrathecal vasodilator, 4) Need for angioplasty</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hydrocephalus</measure>
    <time_frame>Through hospital admission, average of 4 weeks</time_frame>
    <description>Presence of hydrocephalus based on any of the following criteria: 1) Need for temporary CSF diversion via an external ventricular drain, 2) Need for permanent CSF diversion via a ventricular shunt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stressed-induced cardiomyopathy</measure>
    <time_frame>Through hospital admission, average of 4 weeks</time_frame>
    <description>Presence of stressed-induced cardiomyopathy based on any of the following criteria: 1) New troponin elevation, 2) New EKG changes (specifically ST segment elevation, ST segment depression, left bundle branch block, prolonged QT interval), 3) New findings of cardiomyopathy on echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral ischemia</measure>
    <time_frame>Through hospital admission, average of 4 weeks</time_frame>
    <description>Presence of cerebral ischemia based on the following criteria: Radiographic evidence of a new infarct or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>2 years</time_frame>
    <description>Modified Rankin Scale for Neurological Disability (minimum score 0, maximum score 6, better outcomes have lower scores)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Auricular VNS Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive twice daily auricular vagal nerve stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Auricular VNS Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will have an auricular vagal nerve stimulator applied twice daily, without the stimulation applied</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Auricular Vagus Nerve Stimulation</intervention_name>
    <description>Transcutaneous auricular vagal nerve stimulation</description>
    <arm_group_label>Auricular VNS Stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Auricular Vagus nerve Stimulation</intervention_name>
    <description>Transcutaneous auricular vagal nerve ear clip applied without current</description>
    <arm_group_label>Sham Auricular VNS Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Spontaneous subarachnoid hemorrhage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Trauma-induced subarachnoid hemorrhage&#xD;
&#xD;
          -  Ongoing chemotherapy&#xD;
&#xD;
          -  Taking immunosuppressive medications for other medical illnesses&#xD;
&#xD;
          -  Presence of a pacemaker&#xD;
&#xD;
          -  Prolonged bradycardia at time of admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric C Leuthardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna L Huguenard, MD</last_name>
    <phone>3144506698</phone>
    <email>ahuguenard@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Huguenard, MD</last_name>
      <phone>314-450-6698</phone>
      <email>ahuguenard@wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Anna Huguenard</investigator_full_name>
    <investigator_title>Resident Physician</investigator_title>
  </responsible_party>
  <keyword>Vagal nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

